Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy
Abstract The relationship between radiation doses and clinical relapse in patients receiving salvage radiotherapy (SRT) for biochemical recurrence (BCR) after radical prostatectomy (RP) remains unclear. We identified 292 eligible patients treated with SRT between 2005 and 2018 at 15 institutions. Cl...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-50434-4 |
| _version_ | 1797363286471081984 |
|---|---|
| author | Seiya Takano Natsuo Tomita Masanari Niwa Akira Torii Taiki Takaoka Nozomi Kita Kaoru Uchiyama Mikiko Nakanishi-Imai Shiho Ayakawa Masato Iida Yusuke Tsuzuki Shinya Otsuka Yoshihiko Manabe Kento Nomura Yasutaka Ogawa Akifumi Miyakawa Akihiko Miyamoto Shinya Takemoto Takahiro Yasui Akio Hiwatashi |
| author_facet | Seiya Takano Natsuo Tomita Masanari Niwa Akira Torii Taiki Takaoka Nozomi Kita Kaoru Uchiyama Mikiko Nakanishi-Imai Shiho Ayakawa Masato Iida Yusuke Tsuzuki Shinya Otsuka Yoshihiko Manabe Kento Nomura Yasutaka Ogawa Akifumi Miyakawa Akihiko Miyamoto Shinya Takemoto Takahiro Yasui Akio Hiwatashi |
| author_sort | Seiya Takano |
| collection | DOAJ |
| description | Abstract The relationship between radiation doses and clinical relapse in patients receiving salvage radiotherapy (SRT) for biochemical recurrence (BCR) after radical prostatectomy (RP) remains unclear. We identified 292 eligible patients treated with SRT between 2005 and 2018 at 15 institutions. Clinical relapse-free survival (cRFS) between the ≥ 66 Gy (n = 226) and < 66 Gy groups (n = 66) were compared using the Log-rank test, followed by univariate and multivariate analyses and a subgroup analysis. After a median follow-up of 73 months, 6-year biochemical relapse-free survival, cRFS, cancer-specific survival, and overall survival rates were 58, 92, 98, and 94%, respectively. Six-year cRFS rates in the ≥ 66 Gy and < 66 Gy groups were 94 and 87%, respectively (p = 0.022). The multivariate analysis revealed that Gleason score ≥ 8, seminal vesicle involvement, PSA at BCR after RP ≥ 0.5 ng/ml, and a dose < 66 Gy correlated with clinical relapse (p = 0.015, 0.012, 0.024, and 0.0018, respectively). The subgroup analysis showed the consistent benefit of a dose ≥ 66 Gy in patients across most subgroups. Doses ≥ 66 Gy were found to significantly, albeit borderline, increase the risk of late grade ≥ 2 GU toxicity compared to doses < 66 Gy (14% vs. 3.2%, p = 0.055). This large multi-institutional retrospective study demonstrated that a higher SRT dose (≥ 66 Gy) resulted in superior cRFS. |
| first_indexed | 2024-03-08T16:19:11Z |
| format | Article |
| id | doaj.art-28e91be8b9f94b11a46ad5621eb9b775 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-08T16:19:11Z |
| publishDate | 2024-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-28e91be8b9f94b11a46ad5621eb9b7752024-01-07T12:26:33ZengNature PortfolioScientific Reports2045-23222024-01-0114111010.1038/s41598-023-50434-4Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomySeiya Takano0Natsuo Tomita1Masanari Niwa2Akira Torii3Taiki Takaoka4Nozomi Kita5Kaoru Uchiyama6Mikiko Nakanishi-Imai7Shiho Ayakawa8Masato Iida9Yusuke Tsuzuki10Shinya Otsuka11Yoshihiko Manabe12Kento Nomura13Yasutaka Ogawa14Akifumi Miyakawa15Akihiko Miyamoto16Shinya Takemoto17Takahiro Yasui18Akio Hiwatashi19Department of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Kariya Toyota General HospitalDepartment of Radiology, Japanese Red Cross Aichi Medical Center Nagoya Daini HospitalDepartment of Radiology, Japan Community Health Care Organization Chukyo HospitalDepartment of Radiation Oncology, Suzuka General HospitalDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical CenterDepartment of Radiology, Okazaki City HospitalDepartment of Radiation Oncology, Nanbu Tokushukai General HospitalDepartment of Radiotherapy, Nagoya City West Medical CenterDepartment of Radiation Oncology, Kasugai Municipal HospitalDepartment of Radiation Oncology, National Hospital Organization Nagoya Medical CenterDepartment of Radiation Oncology, Hokuto HospitalDepartment of Radiation Oncology, Fujieda Heisei Memorial HospitalDepartment of Urology, Nagoya City University Graduate School of Medical SciencesDepartment of Radiology, Nagoya City University Graduate School of Medical SciencesAbstract The relationship between radiation doses and clinical relapse in patients receiving salvage radiotherapy (SRT) for biochemical recurrence (BCR) after radical prostatectomy (RP) remains unclear. We identified 292 eligible patients treated with SRT between 2005 and 2018 at 15 institutions. Clinical relapse-free survival (cRFS) between the ≥ 66 Gy (n = 226) and < 66 Gy groups (n = 66) were compared using the Log-rank test, followed by univariate and multivariate analyses and a subgroup analysis. After a median follow-up of 73 months, 6-year biochemical relapse-free survival, cRFS, cancer-specific survival, and overall survival rates were 58, 92, 98, and 94%, respectively. Six-year cRFS rates in the ≥ 66 Gy and < 66 Gy groups were 94 and 87%, respectively (p = 0.022). The multivariate analysis revealed that Gleason score ≥ 8, seminal vesicle involvement, PSA at BCR after RP ≥ 0.5 ng/ml, and a dose < 66 Gy correlated with clinical relapse (p = 0.015, 0.012, 0.024, and 0.0018, respectively). The subgroup analysis showed the consistent benefit of a dose ≥ 66 Gy in patients across most subgroups. Doses ≥ 66 Gy were found to significantly, albeit borderline, increase the risk of late grade ≥ 2 GU toxicity compared to doses < 66 Gy (14% vs. 3.2%, p = 0.055). This large multi-institutional retrospective study demonstrated that a higher SRT dose (≥ 66 Gy) resulted in superior cRFS.https://doi.org/10.1038/s41598-023-50434-4 |
| spellingShingle | Seiya Takano Natsuo Tomita Masanari Niwa Akira Torii Taiki Takaoka Nozomi Kita Kaoru Uchiyama Mikiko Nakanishi-Imai Shiho Ayakawa Masato Iida Yusuke Tsuzuki Shinya Otsuka Yoshihiko Manabe Kento Nomura Yasutaka Ogawa Akifumi Miyakawa Akihiko Miyamoto Shinya Takemoto Takahiro Yasui Akio Hiwatashi Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy Scientific Reports |
| title | Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| title_full | Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| title_fullStr | Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| title_full_unstemmed | Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| title_short | Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| title_sort | impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy |
| url | https://doi.org/10.1038/s41598-023-50434-4 |
| work_keys_str_mv | AT seiyatakano impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT natsuotomita impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT masanariniwa impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT akiratorii impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT taikitakaoka impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT nozomikita impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT kaoruuchiyama impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT mikikonakanishiimai impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT shihoayakawa impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT masatoiida impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT yusuketsuzuki impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT shinyaotsuka impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT yoshihikomanabe impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT kentonomura impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT yasutakaogawa impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT akifumimiyakawa impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT akihikomiyamoto impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT shinyatakemoto impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT takahiroyasui impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy AT akiohiwatashi impactofradiationdosesonclinicalrelapseofbiochemicallyrecurrentprostatecancerafterprostatectomy |